What Is Biocad? The Russian Biotechnology Company Explained

Biocad is one of Russia’s largest biotechnology companies, specializing in the development, manufacture, and marketing of biologic drugs for oncology, autoimmune diseases, and other serious conditions. Founded in 2001 and headquartered near Saint Petersburg, the company operates a full production cycle that spans early-stage molecule discovery through mass manufacturing and post-market support. Biocad has built its reputation largely on biosimilars, which are near-copies of expensive originator biologic drugs, but it also pursues original molecules. The company sits at the intersection of Russian industrial policy, global biosimilar competition, and a domestic healthcare system that has pushed hard to reduce dependence on imported medicines.

How Biocad Grew Into a Major Player

Biocad started as a small research outfit, but by the mid-2010s it had become one of the most prominent private biotechnology firms in Russia. The company employs over 1,400 people, more than 650 of whom are scientists and researchers, and it maintains what has been described as a world-level research-and-development center alongside state-of-the-art pharmaceutical and biotechnological manufacturing facilities.¹ Its growth has been fueled in part by the Russian government’s broader import-substitution strategy, which encourages domestic production of medicines that were previously sourced from Western pharmaceutical companies. That policy environment created a ready market for a company capable of producing complex biologic drugs locally.

The company’s corporate structure has involved an offshore holding entity registered in Cyprus, a common arrangement for Russian firms seeking international investment and operational flexibility.¹ At various points, Biocad has attracted investment from major Russian business figures and entities linked to the state’s pharmaceutical strategy, though its ownership structure has shifted over the years. The company has positioned itself not just as a manufacturer but as a vertically integrated operation, claiming to handle everything from the initial identification of a target molecule to the clinical trials needed for regulatory approval and then onward to distribution.

The Biosimilar Business Model

Most of Biocad’s commercially significant products to date are biosimilars. For readers unfamiliar with the term, a biosimilar is a biologic medicine designed to closely match an existing approved biologic, the way a generic pill mimics a brand-name tablet, except that biologics are made from living cells rather than simple chemical synthesis. Because the manufacturing process is so complex, biosimilars are never exact duplicates of the originator drug. Instead, regulators require extensive testing to demonstrate that a biosimilar is sufficiently similar in structure, function, and clinical performance.

Biocad has developed biosimilar versions of several high-profile originator drugs, including trastuzumab (the originator being Herceptin, used in HER2-positive breast cancer), rituximab (Rituxan/MabThera, used in lymphoma and autoimmune diseases), and bevacizumab (Avastin, used in various cancers). In Russia’s healthcare system, where budgets are tightly constrained and the government actively promotes domestic alternatives, biosimilars from companies like Biocad can capture significant market share relatively quickly once approved. The economic logic is straightforward: originator biologics are among the most expensive drugs in the world, and biosimilars offer a path to treating more patients at lower cost.

This strategy is not unique to Russia. Biosimilar development has become a global industry, with companies across India, South Korea, and Europe competing for a share of a market worth tens of billions of dollars. What sets Biocad apart is the degree to which its growth has been intertwined with Russian state policy on pharmaceutical self-sufficiency. The Russian government’s “Pharma 2020” and successor strategies explicitly prioritized reducing dependence on foreign drugmakers, and Biocad was among the domestic firms best positioned to benefit.

Clinical Evidence Behind Biocad’s Trastuzumab Biosimilar

The quality question that hangs over any biosimilar is whether it actually works as well as the original. For Biocad’s trastuzumab biosimilar, designated BCD-022, the answer from a published international phase III trial is that it performed equivalently to reference trastuzumab. The trial enrolled 225 patients with metastatic HER2-positive breast cancer, split roughly evenly between the biosimilar and the originator, with both groups also receiving paclitaxel chemotherapy.²

The overall response rate was about 50% in the BCD-022 group and roughly 44% in the reference trastuzumab group. The difference fell well within the pre-set equivalence margins, meaning the trial was designed to flag a meaningful gap and found none.³ Safety profiles were also similar: adverse events were reported in about 94% of patients in the biosimilar arm and roughly 95% in the reference arm, a difference that is statistically meaningless and reflects the harsh side-effect profile of cancer treatment in general, not a problem specific to either drug.³

This kind of randomized, double-blind equivalence trial is the standard regulators expect for biosimilar approval in most markets. It is worth noting that the trial was international and multicenter, not a purely domestic Russian affair, which adds some credibility to the results. Biocad had also conducted physicochemical and preclinical comparisons before moving to the clinical trial, following the standard biosimilar development pathway.⁴

How Russian Patients Feel About Domestic Biologics

Producing a biosimilar that meets clinical equivalence standards is one challenge. Getting patients to trust it is another. In Russia, the switch from an imported originator biologic to a domestic biosimilar is sometimes made not by the patient’s doctor but at the pharmacy level, during routine dispensing. This matters, because patient experience with the transition varies depending on who makes the call.

A medical and sociological study of patients with relapsing-remitting multiple sclerosis found that about 63% of patients noticed no change after being switched from an originator drug to a domestic version. Roughly 28% reported feeling worse, and about 7% actually felt better.⁵ That “28% felt worse” figure deserves some context. When the switch was initiated by a clinician rather than a pharmacist, the reported rate of clinical deterioration was lower, around 54% of those who noticed any worsening. When the pharmacy made the swap, that figure jumped to 74%.⁵ The implication is that doctor involvement, explanation, and reassurance play a large role in how patients experience a drug switch, a phenomenon well-documented across many therapeutic areas worldwide.

Patient attitudes toward Russian-made disease-modifying therapies were not uniformly negative. On balance, ratings in favor of domestic drugs outweighed ratings against them, and 76% of respondents said they were interested in learning more about how new Russian drugs are developed and registered.⁵ Still, specific product experiences mattered. Patients receiving interferon beta-1b showed the highest negative attitudes toward domestic versions, with 52% giving negative feedback, compared to 20–35% in other treatment groups. Those on interferon beta-1a were more accepting, with only 20% negative.⁵

About 13% of patients stopped taking their medication altogether after the switch, and the likelihood of stopping was much higher when the pharmacy, rather than a clinician, initiated the change. Side effects with the new drug accounted for about a fifth of all treatment discontinuations.⁵ For a company like Biocad, this data points to a clear business problem beyond just manufacturing quality: how the transition is managed at the point of care has a direct impact on whether patients stick with the treatment at all.

International Ambitions and Offices Abroad

Biocad has not confined itself to the Russian market. The company maintains offices and representative branches in the United States, Brazil, China, India, and other countries.¹ Its products have been registered or are seeking registration in several countries across Latin America, the Middle East, and Southeast Asia. This international footprint is typical of ambitious biosimilar makers: the largest revenue opportunities for biosimilars exist in markets where healthcare budgets are growing but cannot afford originator prices, and where regulatory pathways for biosimilar approval are becoming more established.

The geopolitical landscape complicates this picture. Since 2022, Western sanctions on Russia and the broader diplomatic fallout from the conflict in Ukraine have made international partnerships and regulatory approvals more difficult for Russian companies. Biocad’s ability to conduct international clinical trials, source specialized raw materials, and maintain regulatory relationships in Western markets has been affected to varying degrees. Some of the company’s expansion efforts, particularly in emerging markets less aligned with Western sanctions regimes, have continued, but the path to selling biosimilars in the European Union or the United States, always a steep climb for any Russian firm, has become steeper.

At the same time, the sanctions environment has reinforced Russia’s domestic rationale for companies like Biocad. With fewer Western pharmaceutical companies willing or able to supply the Russian market, the government’s push for pharmaceutical self-sufficiency has become not just a policy preference but an operational necessity. Biocad’s role as a domestic supplier of critical biologic drugs has only grown more strategically important within Russia as a result.

Beyond Biosimilars: Original Drug Development

While biosimilars have been Biocad’s commercial backbone, the company has invested in developing original biologic molecules as well. This is a significant step up in ambition and risk. Copying an existing drug, even a complex biologic, is a more predictable endeavor than discovering and developing something entirely new. Original drug development requires identifying a novel target, designing a molecule to hit it, running the full gauntlet of preclinical and clinical trials without the reassuring benchmark of an existing drug’s track record, and then convincing regulators to approve something they have never evaluated before.

Biocad has pursued several original molecules in the oncology and autoimmune spaces. Some of these have entered clinical trials, though the timelines and success rates for novel biologic development are notoriously uncertain everywhere, not just in Russia. The company has also worked on novel formulations and delivery mechanisms for existing classes of biologic therapy, attempting to differentiate itself from the pack of global biosimilar manufacturers that compete largely on price.

Whether Biocad can successfully transition from a primarily biosimilar-focused company to one with a meaningful portfolio of original drugs remains an open question. The economics are challenging: original biologics require vastly more investment, take longer to reach market, and fail more often than biosimilar development programs. But the potential rewards are also much larger, both in terms of revenue per product and in terms of the company’s standing among global biotech peers.

Manufacturing Complexity and Quality Standards

Biologic drugs are manufactured using living cell systems, typically engineered cell lines that produce the target protein under carefully controlled conditions. The resulting product must be purified, tested, and formulated to exacting standards. Subtle variations in the manufacturing process, such as changes in temperature, nutrient media, or fermentation time, can alter the final product in ways that affect how it performs in patients. This is why biosimilar development is so much more demanding than generic small-molecule drug manufacturing, where the chemistry is simpler and the product can be verified by comparing chemical structures directly.

Biocad’s manufacturing facilities near Saint Petersburg are designed to handle this complexity across multiple product lines simultaneously. The company has invested heavily in expanding its production capacity, motivated in part by the government’s preference for domestically manufactured biologics in public procurement. For drugs like trastuzumab and rituximab, where demand is driven by cancer treatment protocols, reliable manufacturing at scale is not just a business advantage but a public health necessity: supply disruptions for a cancer drug can have immediate, serious consequences for patients mid-treatment.

Russian regulatory standards for biosimilar approval have drawn from international frameworks, including elements of the World Health Organization and European Medicines Agency guidelines, though the specifics of how rigorously those standards are applied have been debated by outside observers. The published phase III trial data for BCD-022, for instance, follows the same general structure and statistical methodology that regulators in the EU or the United States would expect, which suggests Biocad is at least aiming to meet international norms even when seeking approval primarily in markets with less stringent requirements.

The Nocebo Effect and Drug Switching

One underappreciated factor in the biosimilar world, relevant to Biocad and every other biosimilar maker, is the nocebo effect: patients who expect a cheaper or unfamiliar drug to work less well may genuinely experience more side effects or reduced efficacy, even when the drug is objectively equivalent. The multiple sclerosis patient data discussed earlier hints at this dynamic. When patients were switched by a pharmacist rather than a clinician, they reported worse outcomes at notably higher rates. This pattern is consistent with the nocebo effect: a switch that feels imposed or unexplained triggers anxiety, which manifests as real symptoms.

Globally, biosimilar manufacturers and health systems have recognized this as a serious barrier to adoption. Some European health systems have invested in structured switching programs that include patient education, clinician-led conversations, and follow-up monitoring specifically designed to reduce nocebo-driven complaints. Biocad and the Russian healthcare system face a version of this same challenge, compounded by historically low public trust in domestically manufactured pharmaceuticals relative to imported Western brands. The patient survey finding that 76% of respondents wanted to learn more about how Russian drugs are developed suggests an appetite for transparency that, if met, could help erode some of the skepticism.

The practical lesson for patients in Russia or any other market where biosimilar switching occurs is that the manner of the switch matters as much as the drug itself. A clinician-led switch with clear communication tends to produce better subjective outcomes than a pharmacy-level substitution without context, regardless of whether the underlying product is any different in quality.

Biocad in the Broader Russian Biotech Landscape

Biocad is not Russia’s only biotechnology company, but it is one of a small handful that operate at a scale comparable to mid-sized international biotech firms. Other Russian players in the space tend to be either smaller specialty firms or state-affiliated research institutes with more limited commercial operations. Biocad’s combination of private-sector agility, significant state support through procurement and policy, and genuine R&D investment in both biosimilars and original molecules gives it a somewhat unusual profile.

The Russian biotechnology sector as a whole remains small relative to the industries in the United States, Europe, or even South Korea and China. Regulatory infrastructure, venture capital ecosystems, and academic-to-industry pipelines are all less developed. Biocad has tried to compensate for some of these structural disadvantages by investing heavily in its own internal research capacity, hence the large share of scientists in its workforce, and by establishing international footholds that give it access to talent and partnerships beyond Russia’s borders.¹

How sustainable this model is under continued geopolitical pressure is a genuinely open question. Biotechnology is an inherently global enterprise: reagents, cell lines, analytical instruments, and clinical-trial networks all cross borders. A company that is partially cut off from Western supply chains and regulatory partnerships faces real constraints on how fast it can grow and how competitive its products can be in the most lucrative markets. For now, Biocad remains a dominant force in Russian domestic healthcare, a growing presence in select international markets, and a company whose trajectory will be shaped as much by geopolitics as by science.

1
Strategic decisions and risk management. THE REACTION OF INDUSTRIAL COMPANIES TO CRISIS: CHANGES IN BUSINESS-MODEL AND STRATEGIC SUSTAINABILITY
2
BMC Cancer. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab
3
BMC Cancer. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab – Section: RESULTS
4
BMC Cancer. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab – Section: BACKGROUND
5
Neurology, Neuropsychiatry, Psychosomatics. Attitude to reproduced disease modifying therapies in patients with relapsing-remitting multiple sclerosis: results of a medical and sociological study